Related Experiment Video

Updated: May 13, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Research needs in the area of device-related treatments for hypertension

Jens Jordan1, Johannes F Mann, Friedrich C Luft

  • 1Hannover Medical School, Institute of Clinical Pharmacology, Hannover, Germany.

Kidney International
|March 1, 2013
PubMed

Insights

New hypertension treatments like renal denervation and carotid sinus stimulation lack crucial data. Evidence-based standards are needed before widespread adoption of these devices.

Area of Science:

  • Cardiovascular medicine
  • Nephrology
  • Medical device technology

Background:

  • Hypertension is a major risk factor for cardiovascular and renal diseases.
  • Existing medications are not effective for all patients.
  • Device-based therapies, including renal denervation and carotid sinus stimulation, are emerging treatments.

Purpose of the Study:

  • To highlight critical data deficiencies in current device-based hypertension treatments.
  • To emphasize the need for evidence-based standards before widespread implementation.

Main Methods:

  • Review of available data on catheter-based renal denervation.
  • Assessment of data for electrical carotid sinus stimulation.
  • Identification of missing histological, functional, and long-term endpoint data.

Main Results:

  • Limited large-animal data exist for renal denervation's impact on arterial histology.
  • Functional data on re-innervation are lacking for both renal denervation and carotid sinus stimulation.
  • Sustained efficacy and long-term endpoint data are unavailable for both treatments.

Conclusions:

  • Significant gaps in basic and clinical data hinder the evaluation of renal denervation and carotid sinus stimulation.
  • Current evidence does not support the widespread introduction of these device-based hypertension therapies.
  • Rigorous, evidence-based standards must be applied to medical devices before clinical adoption.

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...